Chemotherapy for Nasopharyngeal Cancer: Neoadjuvant, Concomitant, and/or Adjuvant
- 552 Downloads
Nasopharyngeal cancers are unique among other head and neck cancers, not only in epidemiology and histological characteristics, but also on treatment strategies as well. Radiotherapy is the primary treatment due to its radiosensitivity. In locally advanced stages, concurrent chemoradiation has been established to be effective to eradicate the disease and improve survival, in favor of radiotherapy alone. While increasing studies have explored the potential benefit of adding more chemotherapy to the concurrent regimen, whether adjuvant or neoadjuvant, it is generally agreed that proper patient selection is needed to stratify high-risk groups to intensify treatment and to optimize the disease outcome. Future studies are ongoing, possibly with the addition of biomarkers such as EBV DNA for risk group stratification. Refinement of patient groups that should be selected for combined modality treatment in stage II disease is also warranted.
KeywordsNasopharyngeal carcinoma Chemotherapy Sequence Efficacy Toxicity Meta-analysis
Compliance with Ethics Guidelines
Conflict of Interest
Wai Tong Ng, Amy T.Y. Chang, Sarah W.M. Lee, Henry C.K. Sze, and Anne W.M. Lee declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 2.Al-Sarraf M, LeBlanc M, Giri PG, et al. Superiority of five year survival with chemoradiotherapy (CT-radiotherapy) vs radiotherapy in patients (Pts) with locally advanced nasopharyngeal cancer (NPC). Intergroup (0099) (SWOG 8892, RTOG 8817, ECOG 2388) phase III study: final report. Proc Am Soc Clin Oncol. 20; Abstract 905.Google Scholar
- 3.Wee J, Tan EH, Tai BC, et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol. 2005;23:6730–8.PubMedCrossRefGoogle Scholar
- 6.••Blanchard P, Lee A, Marguet S, Leclercq J, Ng WT, Ma J, et al. Meta-analysis of chemotherapy in nasopharynx carcinoma (MAC-NPC): an update on 19 trials and 4,806 patients. Lancet Oncol. 2015;16(6):645–55. This updated meta-analysis, with a median follow-up of 7.7 years, is the first analysis to demonstrate the treatment effect of concomitant with or without adjuvant chemotherapy as distinct groups.PubMedCrossRefGoogle Scholar
- 7.Chen Y, Sun Y, Liang SB, et al. Progress report of a randomized trial comparing long-term survival and late toxicity of concurrent chemoradiotherapy with adjuvant chemotherapy versus radiotherapy alone in patients with stage III to IVB nasopharyngeal carcinoma from endemic regions of China. Cancer. 2013;119:2230–8.PubMedCrossRefGoogle Scholar
- 14.•Chen Y, Liu MZ, Liang SB, et al. Preliminary results of a prospective randomized trial comparing concurrent chemoradiotherapy plus adjuvant chemotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma in endemic regions of china. Int J Radiat Oncol Biol Phys. 2008;71:1356–64. This prospective randomized trial demonstrated superior outcome for NPC patient treatment with concurrent chemotherapy and adjuvant chemotherapy compared with radiotherapy alone, with significant improved 2-year OS, failure-free rate, and distant failure-free survival.PubMedCrossRefGoogle Scholar
- 15.Chen L, Hu CS, Chen XZ, et al. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Lancet Oncol. 2012;13:163–71.PubMedCrossRefGoogle Scholar
- 16.What is the best treatment in nasopharyngeal carcinoma? An individual patient data network meta-analysis. Radiother Oncol. 2015; 114 (suppl 1; abstr OC003).Google Scholar
- 20.Fountzilas G, Ciuleanu E, Bobos M, et al. Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma: a randomized phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation. Ann Oncol. 2012;23:427–35.PubMedCrossRefGoogle Scholar
- 22.•Lee AW, Ngan RK, Tung SY, et al. Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fractionation in patients with locoregionally advanced nasopharyngeal carcinoma. Cancer. 2015;121:1328–38. This six-arm randomized phase 3 trial conducted by the Hong Kong Nasopharyngeal Cancer Study Group showed improvement of outcome using induction PX (cisplatin and capecitabine); adjusted comparison of induction PX versus induction or adjuvant PF demonstrated lower hazard ratio of death or progression and less toxicity.PubMedCrossRefGoogle Scholar
- 23.Daoud J, Aupérin A, Tao YG, et al. A randomized trial of concomitant cisplatin-RT +/− induction TPF in locally advanced nasopharyngeal carcinomas. Radiother Oncol. 2015;114 Supp. 1 Abstract OC-004.Google Scholar
- 24.Sun Y, Chen NY, Zhang N, Hu GQ. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregional advanced nasopharyngeal carcinoma: preliminary results of a phase 3 multicentre randomized controlled trial. The Croucher Foundation Advanced Study Institute–Advances in Nasopharyngeal Carcinoma Studies. 2014.Google Scholar
- 28.•Chen QY, Wen YF, Guo L, et al. Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial. J Natl Cancer Inst. 2011;103:1761–70. This randomized study demonstrates benefit of concurrent chemoradiation in stage II nasopharyngeal cancer patients, with significant improvement in 5-year OS, PFS, and distant metastasis-free survival.PubMedCrossRefGoogle Scholar